PT3458067T - Tratamento de distúrbios neurológicos - Google Patents
Tratamento de distúrbios neurológicosInfo
- Publication number
- PT3458067T PT3458067T PT177258621T PT17725862T PT3458067T PT 3458067 T PT3458067 T PT 3458067T PT 177258621 T PT177258621 T PT 177258621T PT 17725862 T PT17725862 T PT 17725862T PT 3458067 T PT3458067 T PT 3458067T
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- neurological disorders
- neurological
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16170107 | 2016-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3458067T true PT3458067T (pt) | 2021-04-07 |
Family
ID=56024138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177258621T PT3458067T (pt) | 2016-05-18 | 2017-05-17 | Tratamento de distúrbios neurológicos |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20190284178A1 (pt) |
| EP (1) | EP3458067B1 (pt) |
| JP (1) | JP6991158B2 (pt) |
| KR (1) | KR102472461B1 (pt) |
| CN (1) | CN109475560B (pt) |
| AU (1) | AU2017265383B2 (pt) |
| CA (1) | CA3022753C (pt) |
| CY (1) | CY1124051T1 (pt) |
| DK (1) | DK3458067T3 (pt) |
| ES (1) | ES2863250T3 (pt) |
| HR (1) | HRP20210477T1 (pt) |
| HU (1) | HUE053494T2 (pt) |
| IL (1) | IL263080B (pt) |
| LT (1) | LT3458067T (pt) |
| MX (1) | MX2018014168A (pt) |
| PL (1) | PL3458067T3 (pt) |
| PT (1) | PT3458067T (pt) |
| RS (1) | RS61655B1 (pt) |
| RU (1) | RU2765868C2 (pt) |
| SG (1) | SG11201809792TA (pt) |
| SI (1) | SI3458067T1 (pt) |
| SM (1) | SMT202100177T1 (pt) |
| TW (1) | TWI753912B (pt) |
| WO (1) | WO2017198346A1 (pt) |
| ZA (1) | ZA201807393B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2863250T3 (es) * | 2016-05-18 | 2021-10-11 | Torqur Ag | Tratamiento de trastornos neurológicos |
| MX2018014167A (es) | 2016-05-18 | 2019-08-16 | Piqur Therapeutics Ag | Tratamiento de lesiones de la piel. |
| SG11202004589SA (en) | 2017-11-23 | 2020-06-29 | Piqur Therapeutics Ag | Treatment of skin disorders |
| CN117396470A (zh) * | 2021-04-09 | 2024-01-12 | 巴塞尔大学 | 作为pi3k的可逆和不可逆共价抑制剂的三嗪衍生物 |
| EP4320115A1 (en) * | 2021-04-09 | 2024-02-14 | Universität Basel | Triazine derivative as reversible and irreversible covalent inhibitors of pi3k |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| MX2008010221A (es) * | 2006-02-09 | 2009-03-05 | Alba Therapeutics Corp | Formulaciones para un efector de union ajustada. |
| TWI498332B (zh) | 2006-04-26 | 2015-09-01 | Hoffmann La Roche | 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物 |
| DK2050749T3 (en) | 2006-08-08 | 2018-01-08 | Chugai Pharmaceutical Co Ltd | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF |
| WO2008098058A1 (en) * | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
| AP2775A (en) | 2008-05-23 | 2013-09-30 | Wyeth Llc | Triazine compounds as P13 kinase and MTOR inhibitors |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| ES2721302T3 (es) | 2013-10-04 | 2019-07-30 | Univ Basel | Inhibidores de PI3k y mTOR conformacionalmente restringidos |
| MA40933A (fr) * | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
| ES2863250T3 (es) * | 2016-05-18 | 2021-10-11 | Torqur Ag | Tratamiento de trastornos neurológicos |
| MX2018014167A (es) * | 2016-05-18 | 2019-08-16 | Piqur Therapeutics Ag | Tratamiento de lesiones de la piel. |
| EP3458035A1 (en) | 2016-05-18 | 2019-03-27 | PIQUR Therapeutics AG | Treatment of skin lesions |
-
2017
- 2017-05-17 ES ES17725862T patent/ES2863250T3/es active Active
- 2017-05-17 RU RU2018140013A patent/RU2765868C2/ru not_active Application Discontinuation
- 2017-05-17 DK DK17725862.1T patent/DK3458067T3/da active
- 2017-05-17 JP JP2018560457A patent/JP6991158B2/ja active Active
- 2017-05-17 SI SI201730696T patent/SI3458067T1/sl unknown
- 2017-05-17 PT PT177258621T patent/PT3458067T/pt unknown
- 2017-05-17 CN CN201780029954.7A patent/CN109475560B/zh active Active
- 2017-05-17 AU AU2017265383A patent/AU2017265383B2/en active Active
- 2017-05-17 SG SG11201809792TA patent/SG11201809792TA/en unknown
- 2017-05-17 US US16/301,729 patent/US20190284178A1/en not_active Abandoned
- 2017-05-17 KR KR1020187035896A patent/KR102472461B1/ko active Active
- 2017-05-17 LT LTEP17725862.1T patent/LT3458067T/lt unknown
- 2017-05-17 MX MX2018014168A patent/MX2018014168A/es unknown
- 2017-05-17 RS RS20210393A patent/RS61655B1/sr unknown
- 2017-05-17 EP EP17725862.1A patent/EP3458067B1/en active Active
- 2017-05-17 WO PCT/EP2017/025136 patent/WO2017198346A1/en not_active Ceased
- 2017-05-17 HU HUE17725862A patent/HUE053494T2/hu unknown
- 2017-05-17 PL PL17725862T patent/PL3458067T3/pl unknown
- 2017-05-17 SM SM20210177T patent/SMT202100177T1/it unknown
- 2017-05-17 CA CA3022753A patent/CA3022753C/en active Active
- 2017-05-17 HR HRP20210477TT patent/HRP20210477T1/hr unknown
- 2017-05-18 TW TW106116465A patent/TWI753912B/zh active
-
2018
- 2018-11-05 ZA ZA2018/07393A patent/ZA201807393B/en unknown
- 2018-11-18 IL IL263080A patent/IL263080B/en unknown
-
2020
- 2020-12-17 US US17/125,012 patent/US11878972B2/en active Active
-
2021
- 2021-03-26 CY CY20211100267T patent/CY1124051T1/el unknown
-
2023
- 2023-12-01 US US18/526,732 patent/US20240343718A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| IL273693A (en) | Treatment of inflammatory disorders | |
| ZA201901279B (en) | Compositions and methods for treatment of neurological disorders | |
| IL285151B1 (en) | Methods for the treatment of fgf21-related disorders | |
| IL267818A (en) | Methods for treating neurological disorders | |
| ZA201903003B (en) | Treatment of neurological diseases | |
| IL267229A (en) | Methods of treating ocular disorders | |
| GB201608046D0 (en) | Treatment of complement-mediated disorders | |
| IL255506A (en) | A method for treating a neurological disease | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| IL314274A (en) | Treatment of skin disorders | |
| IL269604A (en) | Pentides for the treatment of autoimmune diseases | |
| PL3200828T3 (pl) | Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych | |
| IL263080B (en) | Treatment of neurological disorders | |
| GB201612043D0 (en) | Composition for treatment of disorders | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| ZA202002910B (en) | Treatment of skin disorders | |
| SG11201706952VA (en) | Compositions and methods for the treatment of epilepsy and neurological disorders | |
| GB201604359D0 (en) | Treatment of tissue disorders | |
| GB201602784D0 (en) | New treatment of CFTR-related disorders | |
| GB201715763D0 (en) | Treatment of neurological disease | |
| GB201706662D0 (en) | Treatment of neurological diseases | |
| GB201808723D0 (en) | Treatment of hyperproliferative disorders | |
| GB201706823D0 (en) | Treatment of psychological disorders | |
| GB201602641D0 (en) | Treatment of fibrotic disorders |